Sino Biopharmaceutical Ltd.
Industry Group: Pharmaceuticals
Country/Region: Hong Kong
Identifier: HKG:1177
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP’s current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 606 out of 928
Universe
Global Universe 12439 out of 16421
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. |
30.7
High
|
568 out of 928 |
Sino Biopharmaceutical Ltd. |
31.6
High
|
606 out of 928 |
Alkem Laboratories Ltd. |
35.9
High
|
800 out of 928 |
Sichuan Kelun Pharmaceutical Co., Ltd. |
38
High
|
865 out of 928 |
Zhejiang NHU Co. Ltd. |
41.2
Severe
|
911 out of 928 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Sino Biopharmaceutical Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Sino Biopharmaceutical Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Sino Biopharmaceutical Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Sino Biopharmaceutical Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level